Rociletinib

Rociletinib (CO-1686) is an orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR including T790M, and the Ki values for EGFRL858R/T790M and EGFRWT are 21.5 nM and 303.3 nM, respectively.

Product Specifications

CAS Number

[1374640-70-6]

Product Name Alternative

CO-1686; AVL-301; CNX-419

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

EGFR

Type

Reference compound

Related Pathways

JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/CO-1686.html

Purity

99.87

Solubility

DMSO : 125 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

C=CC(NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(C(C)=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1)=O

Molecular Formula

C27H28F3N7O3

Molecular Weight

555.55

Precautions

H302, H315, H319, H335

References & Citations

[1]Walter AO, et al. Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov. 2013 Sep 25.